Increased Proportions of Memory B-Cell Subsets in MS Patients
Overview
This study reveals that multiple sclerosis patients undergoing subcutaneous B-cell depletion therapies exhibit higher proportions of memory B-cell subsets compared to those receiving intravenous therapy. The findings suggest significant immunological differences between the two administration routes.
Background
Multiple sclerosis (MS) is an immune-mediated disease characterized by inflammation and demyelination of the central nervous system. The role of B cells in MS pathogenesis has gained recognition, leading to the development of anti-CD20 monoclonal antibodies that effectively deplete B cells and modulate disease activity. Understanding the immunological effects of different B-cell depletion therapies is crucial for optimizing treatment strategies in MS.
Data Highlights
Group
CD19+ B cells (Median IQR)
CD20+ T cells (Median IQR)
Memory B cells (Median IQR)
Healthy Controls
16.5 (10.1–22.2)
9.1 (6.6–16)
-
Ocre i.v.
0.4 (0.1–0.9)
0.6 (0.1–1)
6.6 (0–13)
Ocre s.c.
0.8 (0.4–1.2)
0.3 (0.2–0.5)
18.4 (4–26.8)
Ofa s.c.
1.7 (0.8–2.2)
0.1 (0.1–0.4)
26.4 (21.1–30)
Key Findings
Both i.v. and s.c. anti-CD20 therapies resulted in significant depletion of CD19+ B cells.
Memory B cell percentages were significantly higher in patients treated with s.c. Ocre and Ofa compared to those treated with i.v. Ocre.
Patients switching from i.v. Ocre to s.c. Ofa showed an increase in memory B cells over time.
i.v. Ocre treatment was associated with lower serum IgG levels compared to healthy controls.
The study highlights the need for further research on the safety and efficacy profiles of different anti-CD20 therapies.
Clinical Implications
Clinicians should consider the differences in immunological effects between i.v. and s.c. anti-CD20 therapies when developing treatment plans for patients with multiple sclerosis. Monitoring memory B cell levels may provide insights into the therapeutic response and long-term outcomes.
Conclusion
The findings underscore the importance of understanding the distinct immunomodulatory effects of different B-cell depletion therapies in multiple sclerosis, which may inform personalized treatment approaches.
by Adriana Krenz, Anna-Lena Krickl, Felix Burner, David Freudenstein, Constantin Träger, Timo Wirth, Luisa Klotz, Klemens Angstwurm, De-Hyung Lee, Ralf A. Linker, Stefanie Haase
